Am the same mate.
Personally I am going to let it ride at this point post FDA approval.
Much like NEU, the real gain comes from the cashflow and expanded pipeline beyond what SB has to offer.
The share price will get a dollar and beyond obviously in my eyes eventaully (this is not advice and just my thoughts).
Matt and co would be silly to take anything less. I doubt they will given what they have. They could quite easily now live off the companies earnings very comfortably.
We also have a team that negotiated the sale of Anacor to Pfizer for $5.2 billion US.
We are in very good hands here in a market that is rotating back into the bio space.
Am the same mate.Personally I am going to let it ride at this...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $346.5M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 21.5¢ | $556.8K | 2.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 188599 | 5 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
21.8¢ |
Change
0.000 ( 1.09 %) |
||||
| Open | High | Low | Volume | ||
| 22.0¢ | 22.0¢ | 21.5¢ | 1397313 | ||
| Last updated 15.59pm 30/04/2024 ? | |||||
| BOT (ASX) Chart |